Full Year 2024 Heidelberg Pharma AG Earnings Call Transcript
Key Points
- Heidelberg Pharma AG (XTER:HPHA) has a strong IP portfolio, particularly in the development of Amanitin as a toxin, which is unique to the company.
- The company is fully financed until 2027, taking into account payments from healthcare royalties.
- HDP-101, the lead program, has shown promising preliminary results in Phase I/IIa trials for multiple myeloma, including a complete response in one patient.
- The partnership with Takeda Oncology is progressing well, with an exclusive license acquired by Takeda for further development of an ATAC.
- The company has secured non-dilutive financing through an agreement with healthcare royalty, extending its cash runway and reducing financial risk.
- Sales revenue and other income decreased from EUR16.8 million in 2023 to EUR12 million in 2024, reflecting lower monetization from partnerships.
- The company reported a net loss of EUR19.4 million for the year, slightly improved from the previous year's loss of EUR20.3 million.
- Current assets decreased from EUR56.6 million to EUR47.6 million, with cash reserves down from EUR43.4 million to EUR29.4 million.
- There is a risk of further delays in FDA approval for TLX250-CDx, which could impact financial planning and cash flow.
- Operating expenses are expected to exceed income over the next few years, indicating ongoing financial challenges.
Good afternoon, ladies and gentlemen and welcome to the Heidelberg Farmer conference call to discuss our 2024 fiscal year results and provide the business update. My name is Andrea Pahl, and I'm the CEO of the company. Joining me on the call today is CFO Walter Miller. Please note that this presentation is available for download on the Heidelberg Pharma website.
The conference call is being recorded, and the replay will be available on our website after the live event. Before we start, please be aware that we were making forward-looking statements on this call as well as during the question answer session. Please see our Safe Harbor statement here.
For more detailed information on the risk and uncertainties affecting our business, please refer to our 2024 management report. It was published last Friday and is available on our website. On the call today, we will give you a brief corporate overview and outline key achievements.
We will also provide an update on our programs; this be followed by a review of our
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
